Anti-Human HLA-DR (MHC Class II) – FITC

Home/Human MHC/Anti-Human HLA-DR (MHC Class II) – FITC

Pricing & Details

Product No.H133
Clone
L243
Protein
HLA-DR Monomorphic
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Major Histocompatibility Class II, MHC class II, HLA-DR Monomorphic
Isotype
Mouse
IgG2a
Prod No.
Size
Price
Avail.
Qty
Add to cart
H133-50 µg
50 µg
$77.00
In stock
Max:
Min: 1
Step: 1
H133-100 µg
100 µg
$148.00
In stock
Max:
Min: 1
Step: 1
H133-200 µg
200 µg
$264.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Baboon
Chimpanzee
Cynomolgus Monkey
Marmoset
Rhesus Monkey
Squirrel Monkey
Canine
Human
Host Species
Mouse
Immunogen
Unknown
Product Concentration
0.2 mg/ml
Formulation
This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day Ambient
Excitation Laser
Blue Laser (490 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this HLA-DR (Clone L243) antibody for staining cells in flow cytometry is ≤ 2.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone L243 recognizes a conformational epitope on the human MHC class II molecule HLA-DRα, which depends on the correct folding of the αβ heterodimer1. It does not cross-react with HLA-DP or HLA-DQ.
Antigen Distribution
HLA-DR is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.
Background
HLA-DR antibody, clone L243, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DR isotype (HLA-DR). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation2. HLA-DR consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain3 encoded by the HLA-DRA and HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens4. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling5. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation6 and can transduce signals into T cells, enhancing T cell proliferation and activity7. HLA-DR expression is a marker of T cell activation and correlates with disease activity in patients with autoimmune disease8 and rapid progression in HIV infection9. Specific alleles of HLA-DR are associated with autoimmune diseases, including rheumatoid arthritis10.

Antigen Details

Ligand/Receptor
CD3/TCR, CD4
Function
Peptide presentation
NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

References & Citations

1. Moro M, Cecconi V, Martinoli C, et al. (2005) BMC Immunol. 6:24
2. Holling TM, et al. (2004) Hum Immunol. 65(4):282-90
3. Mitaksov V, (2006) J Biol Chem. 281(15):10618-25
4. Wieczorek M, et al. (2017) Front Immunol. 8:292
5. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
6. Barnaba V, et al. (1994) Eur J Immunol. 24(1):71-5
7. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60
8. Viallard JF, et al. (2001) Clin Exp Immunol. 125(3):485-491
9. Langford SE, Ananworanich J, Cooper DA. (2007) AIDS Res Ther. 2007;4:11
10. Gough SC, Simmonds MJ. (2007) Curr Genomics. 8(7):453-465

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.